{ "company": "Guardant Health", "ticker": "GH", "period": { "from": "2026-03-01", "to": "2026-03-31", "days": 30 }, "sentiment_breakdown": { "positive": 62, "negative": 83, "neutral": 75 }, "synthesis": { "executive_summary": "**Executive Summary: Guardant Health (GH) Sentiment Analysis - March 2026**\n\nSentiment analysis for Guardant Health (GH) during March 2026 indicates a net negative sentiment across 220 monitored items. The breakdown shows 83 negative items (37.7%), 75 neutral items (34.1%), and 62 positive items (28.2%). The primary driver for positive sentiment was Guardant Health's recognition at the Healthcare Asia Medtech Awards 2026, where its ShieldTM Multi-cancer Detection (MCD) test won Oncology Product Innovation of the Year. This award highlighted the test's 99% overall specificity, 74% sensitivity, and U.S. FDA Breakthrough Device Designation. Conversely, the majority of negative sentiment items were general news articles unrelated to Guardant Health's operations or the broader healthcare industry. The most relevant negative item identified was an advocacy piece urging Congress to fund new colorectal cancer research, reflecting broader industry challenges rather than direct negative news for GH.\n\nDespite the higher volume of negative mentions in the raw data, a closer examination reveals that company-specific news was predominantly positive, driven by significant product innovation and industry recognition for the Shield MCD test. The prevalence of irrelevant general news within the negative category suggests that the overall negative sentiment count may not accurately reflect direct market perception of Guardant Health's performance or outlook. Management should consider refining sentiment source filtering to better gauge direct market reaction to company-specific developments.", "key_findings": [ "✓ Show HN: Open Source 'Conductor + Ghostty'", "✓ Holding it all together: Family caregivers’ support needs after very early supported discharge post stroke", "✓ Guardant Health wins at Healthcare Asia Medtech Awards 2026", "✗ Suspected Armed Robber Killed in Police Operation at Ejura", "✗ Colorectal Cancer Advocates Urge Congress to Fund New Research", "✗ Editorial: Ghana’s Tomato Crisis Is A Policy Failure!" ], "overall_sentiment": "mixed" }, "top_positive": [ { "title": "Show HN: Open Source 'Conductor + Ghostty'", "date": "2026-03-27", "source": "news", "score": 0.883 }, { "title": "Holding it all together: Family caregivers’ support needs after very early supported discharge post stroke", "date": "2026-03-26", "source": "news", "score": 0.88 }, { "title": "Guardant Health wins at Healthcare Asia Medtech Awards 2026", "date": "2026-03-27", "source": "alpha_vantage", "score": 0.772 }, { "title": "Fashion Designer remanded over alleged possession, use of counterfeit money", "date": "2026-03-27", "source": "news", "score": 0.758 }, { "title": "Mikael Barbero: Don't become the next Trivy: how to make your releases, tags, and automation resistant to compromise", "date": "2026-03-26", "source": "news", "score": 0.751 }, { "title": "Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan", "date": "2026-03-30", "source": "alpha_vantage", "score": 0.735 }, { "title": "Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan", "date": "2026-03-30", "source": "reddit", "score": 0.735 }, { "title": "ECG delivers an impressive operational performance in 2025", "date": "2026-03-27", "source": "news", "score": 0.727 }, { "title": "GH’s Marco Star Adrian Anchondo Gets Tribute From Boyfriend After Exit", "date": "2026-03-27", "source": "news", "score": 0.713 }, { "title": "5 Tips to Turn OpenAI Codex Into a Powerful AI Coding Agent", "date": "2026-03-23", "source": "news", "score": 0.691 } ], "top_negative": [ { "title": "Suspected Armed Robber Killed in Police Operation at Ejura", "date": "2026-03-20", "source": "news", "score": -0.963 }, { "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "date": "2026-03-27", "source": "news", "score": -0.945 }, { "title": "Editorial: Ghana’s Tomato Crisis Is A Policy Failure!", "date": "2026-03-24", "source": "news", "score": -0.918 }, { "title": "Businessman Jailed 24 Months for GH¢180,000 Visa Fraud", "date": "2026-03-27", "source": "news", "score": -0.9 }, { "title": "Two Jailed for Stealing Motorbike Worth GH¢10,500", "date": "2026-03-27", "source": "news", "score": -0.883 }, { "title": "Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial", "date": "2026-03-27", "source": "news", "score": -0.869 }, { "title": "Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.869 }, { "title": "Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.", "date": "2026 Mar 4", "source": "pubmed", "score": -0.869 }, { "title": "Dispatch Rider Pleads Guilty To Robbing  Namibian High Commissioner’s Secretary", "date": "2026-03-24", "source": "news", "score": -0.832 }, { "title": "Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.823 } ], "raw_data": { "total_items": 220, "items": [ { "source": "alpha_vantage", "title": "Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan", "url": "https://www.businesswire.com/news/home/20260330846159/en/Guardant-Healths-InfinityAI-Real-World-Evidence-Supports-Approval-of-ENHERTU-for-Previously-Treated-Patients-with-HER2-Positive-Metastatic-Solid-Tumors-in-Japan", "date": "2026-03-30", "summary": "Guardant Health's InfinityAI platform provided crucial real-world evidence, alongside clinical trial data, to support the recent approval of ENHERTU® in Japan. This approval, granted by Japan’s Ministry of Health, Labour and Welfare, is for treating HER2-positive metastatic solid cancers refractory to standard treatments. The collaboration with Daiichi Sankyo highlights the increasing importance of real-world data in expanding access to targeted therapies for rare biomarker-defined patient popul", "sentiment_score": 0.493575, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.735, "confidence": 0.74 } }, { "source": "alpha_vantage", "title": "Guardant Health to present new cancer research while stock trades lower amid strong sell signals", "url": "https://tradersunion.com/news/companies/show/1818093-guardant-health-drops-3-96percent-today/", "date": "2026-03-29", "summary": "Guardant Health is set to present 28 abstracts at the AACR26 event, showcasing advancements in cancer diagnostics and research, particularly in methylation-based tumor classification and multiomic testing. Despite this upcoming presentation of new cancer research, the company's stock has experienced a 3.96% intraday drop, trading lower amid strong sell signals and sustained bearish momentum. Technical indicators suggest further downside risk, with the stock positioned below key moving averages a", "sentiment_score": -0.619402, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Guardant Health Shares Fall as Market Reacts to Conflict, Policy Deadlines | 2026 - News and Statistics", "url": "https://www.indexbox.io/blog/guardant-health-stock-drops-amid-market-uncertainty-and-low-consumer-confidence/", "date": "2026-03-28", "summary": "Guardant Health's stock declined in afternoon trading, reflecting broader market unease fueled by international conflict and upcoming policy deadlines. This market sentiment also pushed consumer confidence to a three-month low, and the company's shares are now trading below their year-to-date peak and are worth less than their value five years ago. The article also provides details on a report about the composite laboratory reagents industry in the United States, including market analysis, trade", "sentiment_score": -0.610985, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": -0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Why Guardant Health (GH) Stock Is Falling Today", "url": "https://www.tradingview.com/news/stockstory:a4995f8d7094b:0-why-guardant-health-gh-stock-is-falling-today/", "date": "2026-03-27", "summary": "Guardant Health (GH) stock fell 3% today due to escalating uncertainty from the U.S.-Iran conflict and Trump administration policy deadlines, which also caused major indices to drop. This follows a 3.4% dip almost a month ago driven by higher-than-expected wholesale inflation data. Guardant Health's shares are highly volatile and have fallen 16.7% year-to-date, trading significantly below its 52-week high.", "sentiment_score": -0.39756, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "Guardant Health wins at Healthcare Asia Medtech Awards 2026", "url": "https://healthcareasiamagazine.com/co-written-partner/event-news/guardant-health-wins-healthcare-asia-medtech-awards-2026", "date": "2026-03-27", "summary": "Guardant Health Pte Ltd won the Oncology Product Innovation of the Year at the Healthcare Asia Medtech Awards 2026 for its ShieldTM Multi-cancer Detection (MCD) test. This blood test screens for 10 types of cancers, demonstrating 99% overall specificity and 74% sensitivity across six aggressive cancers in recent data. The Shield MCD test has also received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).", "sentiment_score": 0.409551, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.772, "confidence": 0.77 } }, { "source": "alpha_vantage", "title": "Tempus AI Reinforces Market Position With Collaborations in 2026", "url": "https://www.tradingview.com/news/zacks:5e5cf70e2094b:0-tempus-ai-reinforces-market-position-with-collaborations-in-2026/", "date": "2026-03-26", "summary": "Tempus AI (TEM) is strengthening its market position in 2026 through strategic collaborations with pharmaceutical companies, healthcare institutions, and technology innovators. These partnerships aim to improve clinical outcomes and accelerate drug development by leveraging Tempus's AI expertise and proprietary platforms. Notable collaborations include work with Daiichi Sankyo on an ADC program, Median Technologies for lung nodule characterization, Blood Cancer United for a pediatric AML registr", "sentiment_score": 0.004, "sentiment_label": "Neutral", "relevance_score": 0.311082, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia", "url": "http://www.msn.com/en-us/health/other/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-25", "summary": "Guardant Health (GH) is partnering with Manulife to introduce its Shield multi-cancer detection test across Asia. This collaboration aims to provide enhanced cancer screening options in the region, leveraging Manulife's network to expand access to Guardant Health's diagnostic technology. The initiative represents a significant step in making advanced multi-cancer detection more widely available.", "sentiment_score": 0.404948, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health Ignites 5.6% Surge: A Volatile Breakout or a Trap for the Unwary?", "url": "https://www.bitget.com/news/detail/12560605304566", "date": "2026-03-25", "summary": "Guardant Health (GH) experienced a 5.63% intraday surge to $89.245, driven by a new partnership with Manulife, despite technical indicators like the RSI being deeply oversold. While the rally shows short-term bullish momentum and potential for breakout past the 30-day moving average, it faces resistance around the $90 psychological barrier and requires sustained movement above $95 to confirm a trend reversal. Options traders are targeting calls with high leverage and liquidity, signaling aggress", "sentiment_score": 0.301922, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Cancer drug researchers gain combined patient and genomics data", "url": "https://www.stocktitan.net/news/GH/verana-health-and-guardant-health-partner-to-advance-precision-2sbofpkxcb3q.html", "date": "2026-03-24", "summary": "Verana Health and Guardant Health have partnered to combine Verana's EHR datasets with Guardant's clinicogenomic testing data, aiming to accelerate oncology drug development and enhance real-world treatment insights. This collaboration expands access to over 95 million patients and more than 30 academic medical centers, providing biopharmaceutical researchers with comprehensive data to understand patient journeys and validate molecular biomarkers. The partnership is expected to streamline drug d", "sentiment_score": 0.348872, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.95035, "sentiment": { "label": "negative", "score": -0.25, "confidence": 0.25 } }, { "source": "alpha_vantage", "title": "Verana and Guardant’s RWE Stack Aims to Solve Precision Oncology’s Data Challenges—Driving Growth Through Recurring Revenue and Broader Data Collections", "url": "https://www.bitget.com/amp/news/detail/12560605299239", "date": "2026-03-24", "summary": "Verana Health and Guardant Health are collaborating to build a robust real-world evidence (RWE) data platform to address precision oncology's data challenges. This partnership integrates Guardant's clinicogenomic datasets with COTA's AI-enhanced oncology data, acquired through Verana's merger, to provide comprehensive insights for drug development. The strategy focuses on high-margin, recurring revenue streams from companion diagnostics and expanding into new therapeutic areas like bladder and p", "sentiment_score": 0.004585, "sentiment_label": "Neutral", "relevance_score": 0.305723, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "alpha_vantage", "title": "Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data", "url": "https://www.prnewswire.com/news-releases/verana-health-and-guardant-health-partner-to-advance-precision-medicine-with-real-world-data-302719285.html", "date": "2026-03-24", "summary": "Verana Health and Guardant Health have partnered to combine their real-world data resources to accelerate precision medicine, particularly in oncology and urology. This collaboration will allow biopharmaceutical researchers to access curated EHR data alongside clinicogenomic testing data, enhancing the understanding of patient journeys and aiding therapy development. The combined data sets will help validate correlations between molecular biomarkers, treatment decisions, and clinical outcomes, a", "sentiment_score": 0.424753, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) director’s RSU vesting adds 264 common shares", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-5b119b371c3f.html", "date": "2026-03-24", "summary": "Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units (RSUs) into common shares. This transaction, part of a routine equity compensation event, increased his direct holdings to 4,487 common shares and 8,184 RSUs. The vested RSUs are from an award granted on November 8, 2024, with a vesting schedule of 25% on the one-year anniversary and the remainder monthly over three years.", "sentiment_score": 0.049968, "sentiment_label": "Neutral", "relevance_score": 0.333448, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-new-manulife-partnersh", "date": "2026-03-23", "summary": "Guardant Health (GH) is under scrutiny after announcing a partnership with Manulife to expand its Shield multi-cancer detection blood test in Asia, starting April 2026. Despite recent share price volatility, the company has shown strong long-term momentum with an 84.77% one-year return, yet some models suggest it's significantly undervalued. The article debates whether the market has already factored in future growth, highlighting potential valuation risks from a high P/S ratio compared to the i", "sentiment_score": 0.287874, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.303, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia", "url": "https://www.msn.com/en-us/health/other/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA", "date": "2026-03-22", "summary": "Guardant Health (GH) has partnered with Manulife to introduce its Shield multi-cancer detection test in Asia. This collaboration aims to provide early cancer detection solutions to a broader population in the region through Manulife's network. The Shield test is designed to detect multiple types of cancer at early stages, potentially improving patient outcomes.", "sentiment_score": 0.430673, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Why Guardant Health’s (GH) 2026 screening story reinforced Piper Sandler’s bullish view", "url": "https://www.msn.com/en-us/money/companies/why-guardant-health-s-gh-2026-screening-story-reinforced-piper-sandler-s-bullish-view/ar-AA1YTUKn?ocid=finance-verthp-feeds", "date": "2026-03-21", "summary": "This article discusses Piper Sandler's maintained bullish outlook on Guardant Health (GH), specifically reinforced by insights from the company's 2026 screening strategy. The analyst firm highlighted a conference presentation that detailed key upcoming milestones and reiterated confidence in Guardant Health's future growth prospects.", "sentiment_score": 0.846956, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia", "url": "https://www.msn.com/en-us/money/general/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA", "date": "2026-03-21", "summary": "Guardant Health (GH) has partnered with Manulife to launch its Shield multi-cancer detection test in Asia. This collaboration aims to make the early cancer detection test accessible to a broader population in the region, leveraging Manulife's network. The Shield test is designed to detect multiple types of cancer from a single blood draw.", "sentiment_score": 0.426724, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Insider Sell: Musa Tariq Sells Shares of Guardant Health Inc (GH)", "url": "https://www.gurufocus.com/news/8728137/insider-sell-musa-tariq-sells-shares-of-guardant-health-inc-gh", "date": "2026-03-20", "summary": "Musa Tariq, a Director at Guardant Health Inc (GH), sold 348 shares of the company on March 18, 2026, bringing his total ownership to 8,394 shares. Over the past year, Tariq has sold a total of 4,489 shares with no purchases. Guardant Health Inc is considered significantly overvalued with a price-to-GF-Value ratio of 1.68, based on its trading price of $88.09 against a GF Value of $52.52.", "sentiment_score": -0.31212, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock", "url": "https://www.marketbeat.com/instant-alerts/insider-selling-guardant-health-nasdaqgh-director-sells-348-shares-of-stock-2026-03-19/", "date": "2026-03-19", "summary": "Guardant Health (NASDAQ:GH) Director Musa Tariq sold 348 shares of the company's stock on March 18, 2026, for a total value of $30,655.32. This sale reduced his stake by 3.98% to 8,394 shares. The company's stock traded up 2.1% to $89.08, and despite missing Q4 EPS estimates, revenue increased by 39.4% year-over-year.", "sentiment_score": -0.214862, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ: GH) director sells 348 company shares", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-426fc16d4cb8.html", "date": "2026-03-19", "summary": "Guardant Health director Tariq Musa sold 348 shares of the company's common stock on March 18, 2026, at an average price of $88.09 per share. This open-market transaction was reported via a Form 4 SEC filing. Following the sale, Musa directly holds 8,394 shares of Guardant Health stock.", "sentiment_score": -0.270516, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) director Tariq Musa sells $30,655 in stock", "url": "https://m.investing.com/news/insider-trading-news/guardant-health-gh-director-tariq-musa-sells-30655-in-stock-93CH-4571897?ampMode=1", "date": "2026-03-19", "summary": "Guardant Health (GH) director Tariq Musa sold 348 shares of common stock for $30,655 on March 18, 2026, bringing his total direct ownership to 8,394 shares. This insider sale occurs as the company's stock trades near $89.08. Separately, Guardant Health recently reported its Q4 2025 results, with several analysts reaffirming or increasing price targets due to strong performance and a positive outlook for commercial expansion and cost management.", "sentiment_score": 0.112683, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics", "url": "https://www.investing.com/news/company-news/cathie-woods-ark-sells-guardant-health-stock-buys-arcturus-therapeutics-93CH-4569651", "date": "2026-03-19", "summary": "Cathie Wood's ARK sold 11,757 shares of Guardant Health (NASDAQ:GH) totaling over $1 million through its ARKG ETF, continuing a trend of reducing its position in the company. Concurrently, ARK purchased 33,864 shares of Arcturus Therapeutics Holdings (NASDAQ:ARCT) for $216,390, indicating a strategic shift towards innovative therapeutics. A smaller sale of Standard Biotools (NASDAQ:LAB) shares also occurred, reflecting ARK's ongoing portfolio reallocation within the biotech sector.", "sentiment_score": -0.394981, "sentiment_label": "Bearish", "relevance_score": 0.960642, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Director at Guardant Health (GH) receives 232 shares via RSUs", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-5d6041acaa59.html", "date": "2026-03-18", "summary": "Guardant Health director Manuel Hidalgo Medina received 232 common shares through the exercise of restricted stock units (RSUs) on March 17, 2026, as part of his equity compensation. These shares were converted at a price of $0.00 per share, increasing his direct holdings to 1,425 shares. The RSU award originated from a grant on July 17, 2024, with a four-year vesting schedule.", "sentiment_score": 0.012507, "sentiment_label": "Neutral", "relevance_score": 0.320473, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ: GH) Form 144 shows proposed insider sale of shares", "url": "https://www.stocktitan.net/sec-filings/GH/144-guardant-health-inc-sec-filing-295c113b5a16.html", "date": "2026-03-18", "summary": "Guardant Health (NASDAQ: GH) has filed a Form 144 indicating proposed insider sales of shares. The filing details planned dispositions of Common Stock linked to restricted stock lapses, with events scheduled for January 15, 2026 (250 shares) and February 15, 2026 (98 shares), handled by Charles Schwab & Co., Inc. This notice acts as a procedural disclosure of intent to sell rather than a record of completed transactions.", "sentiment_score": 0.02006, "sentiment_label": "Neutral", "relevance_score": 0.950924, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership", "url": "https://www.businesswire.com/news/home/20260316025112/en/Guardant-Health-Launches-Shield-Multi-Cancer-Detection-MCD-Test-in-Multiple-Markets-in-Asia-with-Manulife-Partnership", "date": "2026-03-18", "summary": "Guardant Health, Inc. announced the launch of its Shield multi-cancer detection (MCD) test in several Asian markets through a partnership with Manulife. This collaboration will provide eligible Manulife customers in Hong Kong, Singapore, and the Philippines access to the blood-based test, which screens for 10 common cancers, starting in April 2026. The initiative aims to improve early cancer detection and screening participation in a region where cancer remains a leading cause of death.", "sentiment_score": 0.434069, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026", "url": "https://www.biospace.com/press-releases/guardant-health-to-present-28-abstracts-highlighting-advances-in-tumor-typing-therapy-selection-and-expanded-utility-of-multiomic-tissue-and-liquid-biopsy-testing-at-aacr-2026", "date": "2026-03-18", "summary": "Guardant Health and its collaborators will present 28 abstracts, including 3 oral sessions, at the AACR Annual Meeting in April 2026. The presentations will showcase advances in methylation-based tumor classification and liquid biopsy technology, highlighting the utility of Guardant360 Tissue and Guardant360 Liquid in tumor typing and therapy selection. Key data includes high accuracy of Guardant360 Tissue in determining tissue of origin and expanded clinical actionability of Guardant360 Liquid,", "sentiment_score": 0.4852, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Blood tests flag new primary cancers and actionable results in AACR data", "url": "https://www.stocktitan.net/news/GH/guardant-health-to-present-28-abstracts-highlighting-advances-in-bapvicsrazan.html", "date": "2026-03-18", "summary": "Guardant Health will present 28 abstracts at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, highlighting advances in its liquid biopsy technology. Key findings include the high accuracy of Guardant360 Tissue in determining cancer origin, the expanded utility of Guardant360 Liquid in identifying actionable findings for breast and colorectal cancer patients, and Guardant Reveal's potential to detect new primary malignancies during minimal residual disease monitor", "sentiment_score": 0.346551, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ:GH) CFO Sells $261,120.00 in Stock", "url": "https://www.marketbeat.com/instant-alerts/guardant-health-nasdaqgh-cfo-sells-26112000-in-stock-2026-03-17/", "date": "2026-03-18", "summary": "Guardant Health (NASDAQ:GH) CFO Michael Brian Bell sold 3,000 shares of the company's stock for $261,120.00 on March 16, 2026, reducing his stake by 6.44%. The company recently missed EPS expectations in its latest earnings report but exceeded revenue estimates. Guardant Health stock traded at $88.75 mid-day, below its 50-day and 200-day simple moving averages, and institutional investors own approximately 92.6% of the outstanding shares.", "sentiment_score": 0.004656, "sentiment_label": "Neutral", "relevance_score": 0.329477, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ: GH) CLO gains stock through RSU vesting", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-4dd8254703cb.html", "date": "2026-03-17", "summary": "Guardant Health's Chief Legal Officer, John G. Saia, acquired additional common stock through the vesting of performance-based and time-based Restricted Stock Units (RSUs) on March 15, 2026. After the transactions, and accounting for shares withheld for tax obligations, Mr. Saia directly owns 56,903 shares of Guardant Health common stock. The filing details how 4,622 shares were retained by the company at $85.49 per share to cover tax withholdings related to the RSU vesting.", "sentiment_score": 0.021207, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) director acquires 249 shares via RSU vesting", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-78f740c8c862.html", "date": "2026-03-17", "summary": "Guardant Health director Tariq Musa converted 249 restricted stock units (RSUs) into common stock on March 15, 2026, as part of a scheduled vesting. This transaction increased his direct holdings to 8,742 common shares, with an additional 2,999 RSUs remaining. The RSUs, granted on March 6, 2023, vest over four years, with 25% vesting on the first anniversary and the rest monthly over the subsequent three years.", "sentiment_score": 0.036074, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Here’s Why Artisan Small Cap Fund Bets on Guardant Health (GH)", "url": "https://www.insidermonkey.com/blog/heres-why-artisan-small-cap-fund-bets-on-guardant-health-gh-1718418/", "date": "2026-03-17", "summary": "Artisan Small Cap Fund highlighted its new position in Guardant Health, Inc. (NASDAQ: GH) in its Q4 2025 investor letter. Guardant Health specializes in liquid biopsy diagnostics for cancer detection and monitoring. Despite the fund's investment, Insider Monkey suggests that some AI stocks offer greater potential for higher and faster returns than Guardant Health.", "sentiment_score": 0.422577, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Survey Supports Blood Tests for Colorectal Cancer Screening", "url": "https://www.curetoday.com/view/survey-supports-blood-tests-for-colorectal-cancer-screening", "date": "2026-03-17", "summary": "A new national survey indicates that 92% of adults eligible for colorectal cancer screening believe blood-based tests should be widely accessible and covered by insurance. These tests could significantly increase screening participation, with 77% of respondents stating they would be less likely to delay screening if a blood test were available. The survey highlights that blood tests could serve as a crucial entry point to screening, potentially overcoming common barriers associated with traditio", "sentiment_score": 0.424304, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.44, "confidence": 0.44 } }, { "source": "alpha_vantage", "title": "Guardant Health launches Shield Multi-Cancer Detection Test in APAC market", "url": "https://www.biospectrumasia.com/news/54/27363/guardant-health-launches-shield-multi-cancer-detection-test-in-apac-market.html", "date": "2026-03-17", "summary": "Guardant Health has launched its Shield multi-cancer detection (MCD) laboratory developed test (LDT) in key Asian markets including Hong Kong, Singapore, and the Philippines, starting April 2026. This blood test screens for 10 common cancers in average-risk individuals aged 45 or older. The initiative is supported by a partnership with Manulife, aiming to enhance early cancer detection access in the region.", "sentiment_score": 0.471065, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health launches multi-cancer blood test in Asia through Manulife partnership", "url": "https://mugglehead.com/guardant-health-launches-multi-cancer-blood-test-in-asia-through-manulife-partnership/", "date": "2026-03-17", "summary": "Guardant Health (NASDAQ: GH) has launched its Shield multi-cancer detection blood test in several Asian markets through a partnership with Manulife Financial Corporation (TSE: MFC). The test, aimed at individuals aged 45 and older, screens for 10 common cancers using a blood sample. This expansion into Hong Kong, Singapore, and the Philippines, starting in April 2026, aims to improve early cancer detection rates in regions where cancer remains a leading cause of death.", "sentiment_score": 0.456267, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Singapore's Guardant Health launches Shield Multi-Cancer Detection (MCD) Test in APAC market", "url": "https://www.biospectrumasia.com/news/26/27363/singaporesguardant-health-launches-shield-multi-cancer-detection-mcd-test-in-apac-market.html", "date": "2026-03-17", "summary": "Guardant Health has launched its Shield multi-cancer detection (MCD) test in several Asian markets including Hong Kong, Singapore, and the Philippines, starting April 2026. This blood test screens for 10 common cancers in individuals aged 45 or older and aims to enhance early detection and screening participation in the APAC region. The initiative includes a partnership with Manulife, marking a significant step in making innovative early cancer detection technologies accessible.", "sentiment_score": 0.628406, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Blood test that screens for 10 cancers to reach Manulife customers in Asia", "url": "https://www.stocktitan.net/news/GH/guardant-health-launches-shield-multi-cancer-detection-mcd-test-in-0eb8oecxpwvf.html", "date": "2026-03-16", "summary": "Guardant Health has launched its Shield multi-cancer detection (MCD) blood test in several Asian markets through a partnership with Manulife. This methylation-based test screens for 10 common cancer types in individuals aged 45 or older, with access for eligible Manulife customers in Hong Kong, Singapore, and the Philippines beginning in April 2026. The collaboration aims to expand early cancer detection in a region where cancer remains a leading cause of death.", "sentiment_score": 0.461353, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership", "url": "https://finance.yahoo.com/news/guardant-health-launches-shield-multi-120500633.html", "date": "2026-03-16", "summary": "Guardant Health has partnered with Manulife to launch its Shield Multi-Cancer Detection (MCD) test in several Asian markets, including Hong Kong, Singapore, and the Philippines. This collaboration allows eligible Manulife customers to access the blood-based test, which screens for 10 common cancers in individuals aged 45 or older. The initiative aims to enhance early cancer detection efforts in a region where cancer remains a leading cause of death.", "sentiment_score": 0.478683, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "HighVista Strategies LLC Acquires 36,318 Shares of Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-highvista-strategies-llc-acquires-36318-shares-of-guardant-health-inc-gh-2026-03-16/", "date": "2026-03-16", "summary": "HighVista Strategies LLC significantly increased its stake in Guardant Health by 128.5% in the third quarter, acquiring 36,318 additional shares. Despite insiders selling over 20,000 shares, institutional investors now own 92.60% of the company's stock. Guardant Health missed EPS estimates but exceeded revenue expectations, and analysts maintain a \"Moderate Buy\" rating with an average target price of $122.57.", "sentiment_score": 0.120564, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Fred Alger Management LLC Has $39.89 Million Holdings in Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-fred-alger-management-llc-has-3989-million-holdings-in-guardant-health-inc-gh-2026-03-16/", "date": "2026-03-16", "summary": "Fred Alger Management LLC significantly increased its stake in Guardant Health, Inc. (NASDAQ:GH) by 70.9% in the third quarter, now owning 638,487 shares valued at $39.89 million. Despite beating revenue expectations, Guardant Health missed EPS estimates in its latest quarterly report. Analysts largely maintain a bullish outlook on the company, with an average price target of $122.57, though recent insider transactions show both sales and director ownership changes.", "sentiment_score": 0.238266, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.982238, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Is Guardant Health’s (GH) Shield Tour Redefining Its Competitive Moat in Cancer Screening?", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/is-guardant-healths-gh-shield-tour-redefining-its-competitiv", "date": "2026-03-16", "summary": "Guardant Health has launched its \"Shield Across America\" tour to expand the reach of its FDA-approved Shield blood test for colorectal cancer screening, targeting underserved areas and eligible adults. This initiative, supported by new NCCN guidelines and public payer coverage, aims to overcome screening barriers and increase test usage. While the tour reinforces Guardant's investment thesis, the company faces continued risks associated with high cash burn and the long path to profitability desp", "sentiment_score": 0.146572, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Eventide Asset Management LLC Lowers Holdings in Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-eventide-asset-management-llc-lowers-holdings-in-guardant-health-inc-gh-2026-03-15/", "date": "2026-03-15", "summary": "Eventide Asset Management LLC reduced its stake in Guardant Health, Inc. (NASDAQ:GH) by 4.0% in the third quarter, though it remains its largest holding. Despite this reduction and insider selling, Wall Street analysts largely maintain a \"Moderate Buy\" rating with an average price target of $122.57. Guardant Health recently missed EPS expectations but saw strong revenue growth, with institutional investors owning a significant portion of its stock.", "sentiment_score": -0.118472, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "alpha_vantage", "title": "Cinctive Capital Management LP Buys Shares of 121,130 Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-cinctive-capital-management-lp-buys-shares-of-121130-guardant-health-inc-gh-2026-03-15/", "date": "2026-03-15", "summary": "Cinctive Capital Management LP acquired a new position of 121,130 shares in Guardant Health, Inc. (NASDAQ:GH) during the third quarter, valued at approximately $7.57 million. This purchase represents about 0.10% of Guardant Health's stock. Despite significant insider selling totaling $12.2 million in the last quarter, including a substantial sale by CEO Helmy Eltoukhy, the company reported Q4 revenue of $281.3 million, beating expectations with a 39.4% year-over-year increase, though EPS missed ", "sentiment_score": 0.144812, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) Valuation Check As Shield Across America Expands Colorectal Cancer Screening Reach", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-shield-across-america", "date": "2026-03-14", "summary": "Guardant Health (GH) recently launched \"Shield Across America,\" a mobile screening tour for its colorectal cancer blood test, Shield, amidst a 20.53% decline in its 30-day share price but a strong 99.32% 1-year return. Despite short-term price drops, the company's valuation narrative suggests it's 35.5% undervalued at $132.57 per share compared to its current $85.49, driven by significant regulatory and clinical milestones for Shield that promise future revenue growth. However, investors are cau", "sentiment_score": 0.413067, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.599, "confidence": 0.6 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) awards 17,040 RSUs to Chief People Officer Monroe", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-e69d05dc36b9.html", "date": "2026-03-14", "summary": "Guardant Health (GH) has granted 17,040 Restricted Stock Units (RSUs) to its Chief People Officer, Terilyn J. Monroe, on March 11, 2026. These RSUs are part of a routine equity compensation award, not an open-market transaction. The RSUs will vest over a three-year period, with 33% vesting on April 1, 2027, and the remainder vesting in equal quarterly installments over the subsequent two years.", "sentiment_score": 0.036206, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) CFO granted 26,582 RSUs vesting over three years", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-9f1ce93e851c.html", "date": "2026-03-14", "summary": "Guardant Health, Inc.'s CFO, Michael Brian Bell, was granted 26,582 Restricted Stock Units (RSUs) on March 11, 2026, as part of his equity compensation. These RSUs will vest over a three-year period, with 33% vesting on April 1, 2027, and the remaining 67% vesting in equal quarterly installments over the subsequent two years, contingent on continued service. This award is a compensation grant and not an open-market purchase.", "sentiment_score": 0.018677, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "alpha_vantage", "title": "KMI partners with Guardant Health on liquid biopsy cancer screening", "url": "https://www.koreaherald.com/article/10692886", "date": "2026-03-12", "summary": "The Korea Medical Institute (KMI) has signed a memorandum of understanding with US-based Guardant Health to collaborate on liquid biopsy-based precision cancer screening. This partnership aims to develop precision oncology services, including early cancer screening tests and genomic mutation analysis, and establish an integrated cancer management system. The collaboration seeks to enhance diagnostic accuracy and advance precision medicine in Korea.", "sentiment_score": 0.449854, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Quest Diagnostics Expands Preventive Reach With Shield Colorectal Blood Test", "url": "https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/quest-diagnostics-expands-preventive-reach-with-shield-color", "date": "2026-03-11", "summary": "Quest Diagnostics (NYSE:DGX) has partnered with Guardant Health to offer the FDA-approved Shield blood test for colorectal cancer screening, making it available nationwide through Quest’s testing network. This collaboration expands access to preventive care and adds a new product to Quest’s diagnostics menu. The article highlights that this move reinforces Quest's role in preventive testing and its broader push into oncology-related diagnostics, suggesting investors monitor clinical uptake, reim", "sentiment_score": 0.27668, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.874159, "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics", "url": "https://www.businesswire.com/news/home/20260310124738/en/Guardant-Healths-Shield-Blood-based-Screening-Test-for-Colorectal-Cancer-Now-Accessible-Through-National-Test-Ordering-and-Collection-Network-of-Quest-Diagnostics", "date": "2026-03-11", "summary": "Guardant Health's Shield blood-based colorectal cancer screening test is now accessible nationwide through Quest Diagnostics, significantly expanding its reach. This collaboration allows physicians to order Shield through their existing Quest accounts and utilize Quest’s extensive network for blood draws. The Shield test is FDA-approved, covered by Medicare and other networks, and aims to increase screening rates for colorectal cancer, a leading cause of cancer-related deaths.", "sentiment_score": 0.421639, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Hidalgo Medina sells Guardant Health (GH) shares for $118,996", "url": "https://www.investing.com/news/insider-trading-news/hidalgo-medina-sells-guardant-health-gh-shares-for-118996-93CH-4551066", "date": "2026-03-11", "summary": "Manuel Hidalgo Medina, a Director at Guardant Health, Inc. (NASDAQ:GH), sold 1,300 shares of the company's common stock for $118,996 on March 6, 2026, after exercising options for 1,000 shares. Although Guardant Health's stock has surged 154% in the past year, InvestingPro analysis indicates it is currently overvalued. This transaction follows recent positive developments for Guardant Health, including strong Q4 2025 results and increased price targets from several analysts, despite the stock's ", "sentiment_score": -0.141146, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics", "url": "https://nationaltoday.com/us/ca/palo-alto/news/2026/03/10/guardant-healths-shield-blood-based-screening-test-for-colorectal-cancer-now-accessible-through-national-test-ordering-and-collection-network-of-quest-diagnostics/", "date": "2026-03-10", "summary": "Guardant Health's Shield blood-based screening test for colorectal cancer is now accessible through Quest Diagnostics' national network. This partnership aims to increase screening rates for colorectal cancer, the second leading cause of cancer-related deaths in the U.S., by offering a convenient, FDA-approved blood test. The collaboration leverages Quest's extensive infrastructure, including its patient service centers and connectivity with nearly 650,000 clinician accounts, to make the Shield ", "sentiment_score": 0.041398, "sentiment_label": "Neutral", "relevance_score": 0.300624, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Hidalgo Medina sells Guardant Health (GH) shares for $118,996", "url": "https://m.investing.com/news/insider-trading-news/hidalgo-medina-sells-guardant-health-gh-shares-for-118996-93CH-4551066?ampMode=1", "date": "2026-03-10", "summary": "Director Manuel Hidalgo Medina of Guardant Health (NASDAQ:GH) sold 1,300 shares of common stock for $118,996 and exercised options for 1,000 shares for $32,549. This comes amidst recent positive analyst revisions for Guardant Health, including raised price targets from Canaccord Genuity and Stifel, and new coverage from Baird with an Outperform rating. The company also reported strong Q4 2025 Shield product revenue and published a study on its ctDNA blood test for colon cancer recurrence.", "sentiment_score": 0.132121, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook", "description": "Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and liquid biopsy tech Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and li…", "url": "https://www.globenewswire.com/news-release/2026/03/30/3264368/28124/en/Oncology-Biomarkers-Market-Trends-and-Investment-Opportunities-Report-2026-2030-Global-Regional-and-Country-Level-Outlook.html", "date": "2026-03-30", "published_at": "2026-03-30T08:58:00Z", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "news", "source_name": "Pythonbytes.fm", "title": "Python Bytes: #475 Haunted warehouses", "description": "News and announcements from the Python community for the week of Mar 30th, 2026", "url": "https://pythonbytes.fm/episodes/show/475/haunted-warehouses", "date": "2026-03-30", "published_at": "2026-03-30T08:00:00Z", "sentiment": { "label": "negative", "score": -0.477, "confidence": 0.48 } }, { "source": "news", "source_name": "Github.com", "title": "simonw/claude-code-transcripts: Tools for publishing transcripts for Claude Code sessions", "description": "Tools for publishing transcripts for Claude Code sessions - simonw/claude-code-transcripts", "url": "https://github.com/simonw/claude-code-transcripts", "date": "2026-03-30", "published_at": "2026-03-30T05:47:01Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-worktree 0.3.1", "description": "github CLI extension for worktrees", "url": "https://pypi.org/project/gh-worktree/0.3.1/", "date": "2026-03-29", "published_at": "2026-03-29T22:48:33Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "claude-podman added to PyPI", "description": "Run Claude Code CLI in a Podman container with tmux, GitHub access, and persistent config", "url": "https://pypi.org/project/claude-podman/", "date": "2026-03-29", "published_at": "2026-03-29T19:35:55Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Baton – A daemon that sends Claude to fix your GitHub issues", "description": "I got tired of the context-switching loop: pick an issue, read the context, write the code, open a PR, pick the next one. So I built Baton — a Python daemon that polls your GitHub issue tracker and dispatches Claude Code agents to work on them autonomously.Ho…", "url": "https://github.com/mraza007/baton", "date": "2026-03-29", "published_at": "2026-03-29T16:57:05Z", "sentiment": { "label": "negative", "score": -0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Pypi.org", "title": "ansel-cli added to PyPI", "description": "don't leave crumbs in the woods", "url": "https://pypi.org/project/ansel-cli/", "date": "2026-03-29", "published_at": "2026-03-29T16:47:06Z", "sentiment": { "label": "neutral", "score": 0.038, "confidence": 0.04 } }, { "source": "news", "source_name": "Github.com", "title": "GitHub - axeldelafosse/loop: Dead-simple Bun CLI that runs Codex and Claude Code in a loop. · GitHub", "description": "axeldelafosse/loop: Dead-simple Bun CLI that runs Codex and Claude Code in a loop. https://ift.tt/KJUYeRg ai, codex, claude.code, programming", "url": "https://github.com/axeldelafosse/loop", "date": "2026-03-29", "published_at": "2026-03-29T05:47:02Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-worktree 0.3.0", "description": "github CLI extension for worktrees", "url": "https://pypi.org/project/gh-worktree/0.3.0/", "date": "2026-03-28", "published_at": "2026-03-28T23:26:34Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "fastmvc-cli added to PyPI", "description": "FastMVC CLI — interactive FastAPI project generator and tooling", "url": "https://pypi.org/project/fastmvc-cli/", "date": "2026-03-28", "published_at": "2026-03-28T16:33:56Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Open Source 'Conductor + Ghostty'", "description": "Our team works with Claude Code, Codex, Gemini all day.\nWe love Ghostty, but wanted something where we could work in multiple worktree at once and have multiple agents run.We decided to open source the internal team we use. Hope you might find it useful. Free…", "url": "https://github.com/stablyai/orca", "date": "2026-03-27", "published_at": "2026-03-27T22:26:40Z", "sentiment": { "label": "positive", "score": 0.883, "confidence": 0.88 } }, { "source": "news", "source_name": "Pypi.org", "title": "acp-gh 1.4.0", "description": "Automatic Commit Pusher (acp) - CLI tool to create GitHub PRs from staged changes in a single command", "url": "https://pypi.org/project/acp-gh/1.4.0/", "date": "2026-03-27", "published_at": "2026-03-27T21:39:52Z", "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "news", "source_name": "Github.com", "title": "Velxio 2.0 – Emulate Arduino, ESP32, and Raspberry Pi 3 in the Browser", "description": "Emulate Arduino, ESP32 & Raspberry Pi. in your browser. Write code, compile, and run on 19 real boards — Arduino Uno, ESP32, ESP32-C3, Raspberry Pi Pico, Raspberry Pi 3, and more. No hardware, ...", "url": "https://github.com/davidmonterocrespo24/velxio", "date": "2026-03-27", "published_at": "2026-03-27T20:44:33Z", "sentiment": { "label": "negative", "score": -0.36, "confidence": 0.36 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "description": "With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263970/0/en/Colorectal-Cancer-Advocates-Urge-Congress-to-Fund-New-Research.html", "date": "2026-03-27", "published_at": "2026-03-27T16:31:00Z", "sentiment": { "label": "negative", "score": -0.945, "confidence": 0.95 } }, { "source": "news", "source_name": "Plos.org", "title": "Glucocorticoid-Induced alterations in DNA methylation in the H19 promoter of Bone Marrow-Derived Mesenchymal Stem Cells are associated with the pathogenesis of osteonecrosis", "description": "Background Glucocorticoid (GC)-induced osteonecrosis of the femoral head (ONFH) involves bone marrow-derived mesenchymal stem cell (BMSC) apoptosis and dysregulated osteo-adipogenic differentiation. While aberrant H19 promoter methylation and expression have …", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345372", "date": "2026-03-27", "published_at": "2026-03-27T14:00:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Zinc Chemicals Market to Reach USD 16.17 Billion by 2035, Fueled by Rising Demand in Rubber, Agriculture, and Industrial Applications | Research by SNS Insider", "description": "The Zinc Chemicals Market is growing steadily as demand rises for zinc-based fertilizers, rubber additives, and industrial formulations, with the U.S. segment increasing from USD 1.86 billion in 2025 to USD 2.82 billion by 2035. The Zinc Chemicals Market is g…", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263802/0/en/Zinc-Chemicals-Market-to-Reach-USD-16-17-Billion-by-2035-Fueled-by-Rising-Demand-in-Rubber-Agriculture-and-Industrial-Applications-Research-by-SNS-Insider.html", "date": "2026-03-27", "published_at": "2026-03-27T13:30:00Z", "sentiment": { "label": "negative", "score": -0.052, "confidence": 0.05 } }, { "source": "news", "source_name": "Pypi.org", "title": "caalm added to PyPI", "description": "Carbohydrate Activity Annotation with protein Language Models", "url": "https://pypi.org/project/caalm/", "date": "2026-03-27", "published_at": "2026-03-27T08:29:51Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Two Jailed for Stealing Motorbike Worth GH¢10,500", "description": "The Circuit Court at Dansoman has sentenced two young men to prison for stealing a motorbike valued at GH¢10,500. The convicts, Abdul Aziz Osman, 20, unemployed and Abdul Aziz Mohammed, 22, also unemployed, were sentenced by the court presided over by Her Hon…", "url": "https://thechronicle.com.gh/two-jailed-for-stealing-motorbike-worth-gh¢10500/", "date": "2026-03-27", "published_at": "2026-03-27T08:00:45Z", "sentiment": { "label": "negative", "score": -0.883, "confidence": 0.88 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Fashion Designer remanded over alleged possession, use of counterfeit money", "description": "The Circuit Court in Tarkwa, presided over by Her Honour Bernice Mensimah Ackon, has remanded a 40-year-old fashion designer, Grace Arthur, into custody for allegedly possessing and uttering counterfeit Ghana cedi notes at Wasa Akropong in the Western Region.…", "url": "https://thechronicle.com.gh/fashion-designer-remanded-over-alleged-possession-use-of-counterfeit-money/", "date": "2026-03-27", "published_at": "2026-03-27T07:58:51Z", "sentiment": { "label": "positive", "score": 0.758, "confidence": 0.76 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Businessman Jailed 24 Months for GH¢180,000 Visa Fraud", "description": "The Dansoman Circuit Court has sentenced a 29-year-old businessman, Charles Komla Asigbey, to 24 months imprisonment for defrauding seven persons of GH¢180,000 under the pretext of securing visas for them to travel abroad. The court, presided over by Her Hono…", "url": "https://thechronicle.com.gh/businessman-jailed-24-months-for-gh¢180000-visa-fraud/", "date": "2026-03-27", "published_at": "2026-03-27T07:56:52Z", "sentiment": { "label": "negative", "score": -0.9, "confidence": 0.9 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "ECG delivers an impressive operational performance in 2025", "description": "The Eastern Regional office of the Electricity Company of Ghana (ECG) has delivered an impressive operational performance in 2025, underpinned by improved power stability, strategic infrastructure investments, and a renewed crackdown on illegal electricity us…", "url": "https://thechronicle.com.gh/ecg-delivers-an-impressive-operational-performance-in-2025/", "date": "2026-03-27", "published_at": "2026-03-27T07:46:12Z", "sentiment": { "label": "positive", "score": 0.727, "confidence": 0.73 } }, { "source": "news", "source_name": "ComingSoon.net", "title": "GH’s Marco Star Adrian Anchondo Gets Tribute From Boyfriend After Exit", "description": "Fans have bid farewell to General Hospital‘s Marco, portrayed by Adrian Anchondo, and his boyfriend has now shared his reaction to his exit. Fellow soap opera star Colton Little shared an emotional tribute after Anchondo’s surprise departure from GH. Adrian A…", "url": "https://www.comingsoon.net/tv/news/2112893-general-hospital-gh-adrian-anchondo-leave-exit-marco-death-reaction", "date": "2026-03-27", "published_at": "2026-03-27T05:24:50Z", "sentiment": { "label": "positive", "score": 0.713, "confidence": 0.71 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Haruna Iddrisu throws $27,000 lifeline for fourth surgery of six-year-old boy", "description": "The Member of Parliament for Tamale North, Haruna Iddrisu, has funded a fourth life-saving surgery for a six-year-old boy, Abdula Hannan at the KomfoAnokye Teaching Hospital.The little boy has a prolonged medical condition caused by accidental ingestion of a …", "url": "https://thechronicle.com.gh/haruna-iddrisu-throws-27000-lifeline-for-fourth-surgery-of-six-year-old-boy/", "date": "2026-03-27", "published_at": "2026-03-27T00:41:00Z", "sentiment": { "label": "negative", "score": -0.077, "confidence": 0.08 } }, { "source": "news", "source_name": "Nature.com", "title": "Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial", "description": "In the nonpivotal stage 1 of the randomized phase 3 PRESERVE-003 trial, patients with immunochemotherapy-resistant metastatic squamous non-small cell lung cancer without actionable genomic alterations treated with the next-generation, pH-sensitive anti-CTLA-4…", "url": "https://www.nature.com/articles/s41591-026-04323-8", "date": "2026-03-27", "published_at": "2026-03-27T00:00:00Z", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "news", "source_name": "Royal Society of Chemistry", "title": "Atmosphere-dependent synthesis and crystallization behavior of silica nanoparticles derived from rice husk biomass", "description": "RSC Adv., 2026, 16,16874-16886DOI: 10.1039/D6RA00367B, Paper Open Access   This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.Fuad Hama Shareef Radha, Mohammad Tahir Kareem, Omed Gh. AbdullahThis work on sustainable nanomat…", "url": "https://pubs.rsc.org/en/content/articlelanding/2026/ra/d6ra00367b", "date": "2026-03-27", "published_at": "2026-03-27T00:00:00Z", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Pypi.org", "title": "ticktick-agent-cli added to PyPI", "description": "Agent-native CLI for TickTick task management — full API coverage via V1 + V2", "url": "https://pypi.org/project/ticktick-agent-cli/", "date": "2026-03-26", "published_at": "2026-03-26T23:19:31Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results", "description": "NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:", "url": "https://www.globenewswire.com/news-release/2026/03/26/3263407/0/en/IMDX-Submits-GraftAssureDx-for-FDA-Review-and-Reports-Q4-2025-Results.html", "date": "2026-03-26", "published_at": "2026-03-26T20:05:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-license 0.4.0", "description": "Scan github, bitbucket or other providers repositories for missing license files and add them", "url": "https://pypi.org/project/gh-license/0.4.0/", "date": "2026-03-26", "published_at": "2026-03-26T18:26:05Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Pypi.org", "title": "rcpilot added to PyPI", "description": "Lightweight self-hosted session manager for Claude Code Remote Control", "url": "https://pypi.org/project/rcpilot/", "date": "2026-03-26", "published_at": "2026-03-26T17:43:19Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Ssrf.dev", "title": "個人的にGitHub Actionsまわりで気をつけていること | ssrf.dev", "description": "目次ghalint / actionlintに頼る3rd party actionをできるだけ使わないSecretsにKeyを置かないやろうと思っているけど徹底できていないことRequire actions to be pinned to a full-length commit SHAの有効化branch ruleset / push rulesetghalint / actionlintを全リポジトリで回すさいごに 2026年も引き続きGitHub Ac...", "url": "https://ssrf.dev/posts/2026/03/27/personal-gha-security-tips/", "date": "2026-03-26", "published_at": "2026-03-26T16:50:38Z", "sentiment": { "label": "positive", "score": 0.599, "confidence": 0.6 } }, { "source": "news", "source_name": "Plos.org", "title": "Repurposing mebendazole to reprogram oncogenic and tumor-suppressor networks: Multi-cancer insights from ENOX2, MMP2, RASSF1A, WFDC10A and METTL7A", "description": "Background Cancer progression involves coordinated regulation of oncogenes and tumor suppressors. This study explores the interplay of ENOX2 (ecto-NADH oxidase disulfide-thiol exchanger 2), MMP2 (matrix metalloproteinase-2), and regulatory genes Ras Associati…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345701", "date": "2026-03-26", "published_at": "2026-03-26T14:00:00Z", "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "news", "source_name": "Plos.org", "title": "Holding it all together: Family caregivers’ support needs after very early supported discharge post stroke", "description": "Background Early supported discharge (ESD) facilitates the transition from specialized stroke units to home-based rehabilitation in familiar environments. While ESD has shown positive outcomes for people with stroke, little is known about how their family car…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345795", "date": "2026-03-26", "published_at": "2026-03-26T14:00:00Z", "sentiment": { "label": "positive", "score": 0.88, "confidence": 0.88 } }, { "source": "news", "source_name": "Plos.org", "title": "Cell cycle dynamics regulate H3K27 and H3K9 histone modifications in Drosophila", "description": "Previous studies have established a link between cell cycle progression and histone modification dynamics, but how this is regulated in vivo has remained largely explored. This study shows that the levels of H3K27ac, H3K27me3, and H3K9me3 are tightly linked t…", "url": "https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003371", "date": "2026-03-26", "published_at": "2026-03-26T14:00:00Z", "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "news", "source_name": "Pypi.org", "title": "ghboot added to PyPI", "description": "Bootstrap an empty directory into a git repo with a GitHub remote", "url": "https://pypi.org/project/ghboot/", "date": "2026-03-26", "published_at": "2026-03-26T12:06:22Z", "sentiment": { "label": "negative", "score": -0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "Barbero.tech", "title": "Mikael Barbero: Don't become the next Trivy: how to make your releases, tags, and automation resistant to compromise", "description": "This is Part 2 of our response to the Trivy supply-chain compromise. Part 1 covered how to consume GitHub Actions safely. This post covers the other side: how to publish safely, so your project doesn’t become the upstream incident that impacts everyone downst…", "url": "https://mikael.barbero.tech/blog/post/2026-03-26-dont-become-the-next-trivy/", "date": "2026-03-26", "published_at": "2026-03-26T08:30:00Z", "sentiment": { "label": "positive", "score": 0.751, "confidence": 0.75 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "MIIF Records GH¢5.3bn in Mineral Royalties in 2025 – Up from GH¢4.91bn in 2024", "description": "When the Chief Executive Officer (CEO) of the Minerals Income Investment Fund (MIIF), Justina Nelson, addressed editors and senior journalists in Accra, yesterday, she set the tone with a defining statistic, MIIF recorded GH¢5.3 billion in mineral royalties i…", "url": "https://thechronicle.com.gh/miif-records-gh¢5-3bn-in-mineral-royalties-in-2025-up-from-gh¢4-91bn-in-2024/", "date": "2026-03-26", "published_at": "2026-03-26T08:15:50Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Rising Kidney Disease Burden Triggers Fresh Push for Food Labelling Reform", "description": "A growing body of scientific and public health evidence is raising alarms over the rapid rise of Chronic Kidney Disease (CKD) in Ghana. Policy advocates are now calling for urgent reforms to the country’s food labelling system to curb what they describe as a …", "url": "https://thechronicle.com.gh/rising-kidney-disease-burden-triggers-fresh-push-for-food-labelling-reform/", "date": "2026-03-26", "published_at": "2026-03-26T08:06:08Z", "sentiment": { "label": "negative", "score": -0.052, "confidence": 0.05 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Editorial: Ghana Is Paying Billions To Treat A Disease It Could Have Prevented", "description": "Four million Ghanaians, according to available statistics, are living with chronic kidney disease, but regrettably, most of them do not know it. The condition advances without symptoms, recruiting patients silently until it reaches the stage where the only av…", "url": "https://thechronicle.com.gh/editorial-ghana-is-paying-billions-to-treat-a-disease-it-could-have-prevented/", "date": "2026-03-26", "published_at": "2026-03-26T07:58:11Z", "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } }, { "source": "news", "source_name": "Biblegateway.com", "title": "Chronological Reading for Thursday March 26, 2026 (NIV)", "description": "", "url": "https://www.biblegateway.com/reading-plans/chronological/2026/03/26/", "date": "2026-03-26", "published_at": "2026-03-26T04:05:04Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Eclipsesource.com", "title": "The Eclipse Theia Community Release 2026-02", "description": "We are happy to announce the thirteenth Eclipse Theia community release, “2026-02,” incorporating the latest advances from Theia releases 1.67 and 1.68.\nNew to Eclipse Theia? It is the next-generation …The post The Eclipse Theia Community Release 2026-02\nappe…", "url": "https://eclipsesource.com/blogs/2026/03/26/the-eclipse-theia-community-release-2026-02/", "date": "2026-03-26", "published_at": "2026-03-26T00:00:00Z", "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Sift – local, de-noised GitHub notifications", "description": "Sift is an open source local GitHub inbox organizer.GitHub notifications are good at collecting activity and weak at prioritizing it. Sift pulls your inbox and adjacent repo activity into a local SQLite database, classifies it with explicit rules, and gives y…", "url": "https://github.com/vignesh07/sift", "date": "2026-03-25", "published_at": "2026-03-25T17:39:07Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD", "description": "DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced two peer-reviewed …", "url": "https://www.globenewswire.com/news-release/2026/03/25/3262385/0/en/GH-Research-Announces-Publication-of-Phase-2b-Results-for-Mebufotenin-GH001-in-JAMA-Psychiatry-and-Reports-New-Finding-of-Severity-Independent-Efficacy-in-TRD.html", "date": "2026-03-25", "published_at": "2026-03-25T15:10:00Z", "sentiment": { "label": "negative", "score": -0.178, "confidence": 0.18 } }, { "source": "news", "source_name": "Plos.org", "title": "Assessment of long COVID symptom burden in patients testing positive for SARS-CoV-2 at a nationwide retail pharmacy", "description": "Background Numerous grouping and scoring methodologies have been proposed to assess long COVID symptomatology. One approach is to use symptom count as a simple, quantifiable measure of long COVID symptom burden. Methods This was a secondary analysis of a na…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345639", "date": "2026-03-25", "published_at": "2026-03-25T14:00:00Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Plos.org", "title": "M5 positive allosteric modulation alleviates parkinsonian motor deficits", "description": "Parkinson’s disease is a neurodegenerative movement disorder which is characterized by cardinal motor symptoms of tremor at rest, rigidity, bradykineasia, and postural instability. Underlying these cardinal motor symptoms is thought to be death and dysfunctio…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345115", "date": "2026-03-25", "published_at": "2026-03-25T14:00:00Z", "sentiment": { "label": "negative", "score": -0.572, "confidence": 0.57 } }, { "source": "news", "source_name": "Pypi.org", "title": "graniteclaw added to PyPI", "description": "Agent specification certification pipeline — from skill specs to governed, certified Mellea pipelines", "url": "https://pypi.org/project/graniteclaw/", "date": "2026-03-25", "published_at": "2026-03-25T12:43:20Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Clinic – Connect your agent to Gmail, GitHub, Notion and 39 more (OSS)", "description": "Your AI agent can't access your Gmail, your GitHub, or your Notion. Most of these services already have CLIs built for programmatic access, but nobody's set them up, authenticated them, and told the agent they're there.Clinic does it in one command: clinic in…", "url": "https://github.com/jwvictor/clinic", "date": "2026-03-25", "published_at": "2026-03-25T12:42:39Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "OSP withdraws charges against two accused in NPA Trial", "description": "The Office of the Special Prosecutor (OSP) has withdrawn charges against two persons who were standing trial together with former Chief Executive of the National Petroleum Authority (NPA), Dr Mustapha Abdul-Hamid, and others in an alleged extortion case. The …", "url": "https://thechronicle.com.gh/osp-withdraws-charges-against-two-accused-in-npa-trial/", "date": "2026-03-25", "published_at": "2026-03-25T09:29:03Z", "sentiment": { "label": "negative", "score": -0.34, "confidence": 0.34 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "What Does GH Research PLC (GHRS)’s Clinical Progress Updates Say?", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_4821a93d-833b-4229-a256-4e7bc617a16b", "date": "2026-03-25", "published_at": "2026-03-25T05:34:14Z", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "news", "source_name": "Hacker News", "title": "Show HN: GitHub Actions for Agents", "description": "Hi everyone,I really dislike the fix, commit, and wait loop that is involved with CI. I decided to fix that by shortening the loop. I did that by mocking the GH Actions control pane: the runner is the official GH runner, but the API is a mock.What you get is …", "url": "https://news.ycombinator.com/item?id=47513068", "date": "2026-03-25", "published_at": "2026-03-25T03:56:51Z", "sentiment": { "label": "negative", "score": -0.295, "confidence": 0.3 } }, { "source": "news", "source_name": "Frontendfoc.us", "title": "The Great CSS Expansion: Replacing JS with native features", "description": "\n
\n \n
\n\n
\n
\n\n
\n \n \n \n \n USD93.91", "text": "Ticker: **GH**\n\nExchange: **NASDAQ**\n\nTime: **3 Mar 2026 @ 15:35**\n\nPrice: **USD93.91**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/GH/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-03-03", "url": "https://reddit.com/r/getagraph/comments/1rk0rxn/buy_signal_guardant_health_inc_3_mar_2026_1535/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "DeepFuckingValue", "title": "After-Hours Gainers and Losers for Today (March 24, 2026) 📈 📉", "text": "Here are today's top after-hours performers showing the biggest moves after regular trading hours.\n\n## 📈 After-Hours Gainers:\n\n| Symbol | Company | After-Hours | Regular Hours | Change | %Change |\n|:-------|:--------|:----------:|:-------------:|:------:|:-------:|\n| [ARM](https://marketrodeo.com/asset/ARM) | Arm Holdings plc American Depositary Shares | 144.76 | 134.96 | +9.80 | +7.26% |\n| [LTM](https://marketrodeo.com/asset/LTM) | LATAM Airlines Group S.A. | 51.50 | 49.03 | +2.47 | +5.04% |\n| ", "author": "MarketRodeo", "score": 3, "num_comments": 0, "date": "2026-03-24", "url": "https://reddit.com/r/DeepFuckingValue/comments/1s2qaha/afterhours_gainers_and_losers_for_today_march_24/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "reddit", "subreddit": "DeepFuckingValue", "title": "After-Hours Gainers and Losers for Today (March 13, 2026) 📈 📉", "text": "Here are today's top after-hours performers showing the biggest moves after regular trading hours.\n\n## 📈 After-Hours Gainers:\n\n| Symbol | Company | After-Hours | Regular Hours | Change | %Change |\n|:-------|:--------|:----------:|:-------------:|:------:|:-------:|\n| [CHKP](https://marketrodeo.com/asset/CHKP) | Check Point Software Technologies Ltd. | 181.23 | 153.65 | +27.58 | +17.95% |\n| [STLD](https://marketrodeo.com/asset/STLD) | Steel Dynamics, Inc. | 199.24 | 170.60 | +28.64 | +16.79% |\n| ", "author": "MarketRodeo", "score": 3, "num_comments": 1, "date": "2026-03-13", "url": "https://reddit.com/r/DeepFuckingValue/comments/1rszlgw/afterhours_gainers_and_losers_for_today_march_13/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "reddit", "subreddit": "Swing_Trader_Trading", "title": "Middle East war begins – stocks drop – Update 03/09/26", "text": "[Blog Post:](https://positiontrader.blog/2026/03/09/middle-east-war-begins-stocks-drop-update-03-09-26/)\n\nhttps://preview.redd.it/kf19dhculjng1.png?width=877&format=png&auto=webp&s=5f11966e2029af18cd9e91fec37a0655543a614d\n\n* [**Quant 30** ](https://positiontrader.blog/2026/03/09/middle-east-war-begins-stocks-drop-update-03-09-26/#portfolio)**– Up over 26% since June 2025**\n* **Quant Weekly – Up over 27% since June** **2025**\n* **Legacy – Up over 270% since April 2023**\n* [**Education** ](https:/", "author": "Swing_Trader_Trading", "score": 2, "num_comments": 1, "date": "2026-03-09", "url": "https://reddit.com/r/Swing_Trader_Trading/comments/1roycq7/middle_east_war_begins_stocks_drop_update_030926/", "sentiment": { "label": "negative", "score": -0.718, "confidence": 0.72 } }, { "source": "reddit", "subreddit": "Swing_Trader_Trading", "title": "Extreme fear grips the stock market – stock drop slows – Update 03/16/26", "text": "[Blog Post:](https://positiontrader.blog/2026/03/16/extreme-fear-grips-the-stock-market-stock-drop-slows-update-03-16-26/)\n\nhttps://preview.redd.it/ol6riok5g2pg1.png?width=1793&format=png&auto=webp&s=5d0155bc6fd0f1b0fafa9d68bccc95c29c00823d\n\n* [**Quant 30** ](https://positiontrader.blog/2026/03/16/extreme-fear-grips-the-stock-market-stock-drop-slows-update-03-16-26/#portfolio)**– Up over 24% since June 2025**\n* **Quant Weekly – Up over 26% since June** **2025**\n* **Legacy – Up over 270% since Ap", "author": "Swing_Trader_Trading", "score": 2, "num_comments": 0, "date": "2026-03-16", "url": "https://reddit.com/r/Swing_Trader_Trading/comments/1rv7j7d/extreme_fear_grips_the_stock_market_stock_drop/", "sentiment": { "label": "negative", "score": -0.68, "confidence": 0.68 } }, { "source": "reddit", "subreddit": "pancreaticcancer", "title": "Guardant liquid biopsy BRCA2", "text": "anyone have Guardant and have something as 0.3% and it be relevant on tissue. my husband has several markers but two of ones that popped up as low level BRCA2 Y3308 as 0.3% and wondering if it's just noise. waiting for tissue but just curious. He has some that are higher but I'm pretty sure they can't be targeted. Thanks in advance.", "author": "Any_Tumbleweed_7601", "score": 4, "num_comments": 4, "date": "2026-03-29", "url": "https://reddit.com/r/pancreaticcancer/comments/1s71r2e/guardant_liquid_biopsy_brca2/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan", "text": "", "author": "Quantisnow", "score": 1, "num_comments": 0, "date": "2026-03-30", "url": "https://reddit.com/r/Quantisnow/comments/1s7opko/guardant_healths_infinityai_realworld_evidence/", "sentiment": { "label": "positive", "score": 0.735, "confidence": 0.74 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data", "text": "", "author": "Quantisnow", "score": 1, "num_comments": 0, "date": "2026-03-24", "url": "https://reddit.com/r/Quantisnow/comments/1s2dj2p/verana_health_and_guardant_health_partner_to/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "RWATimes", "title": "Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection ...", "text": "![](https://mms.businesswire.com/media/20260318529389/en/1330243/22/GuardantHealthLogo_TM_RGB-2C.jpg)\n\n-Guardant Reveal demonstrates expanded utility in identifying new, primary cancers during minimal residual disease (MRD) monitoringStudies show strong performance of Guardant360 Tissue in determining ...\n\n **Details:**\n- **Published:** 18/03/2026 12:05 (UTC)\n- **📊 Characteristics Score:**\n > **Asset Type:** *others*\n > **Sentiment:** `0.3`\n > **Entropy:** `0.75`\n > **Relevance:** `0.9`\n >", "author": "rwatimes", "score": 1, "num_comments": 0, "date": "2026-03-22", "url": "https://reddit.com/r/RWATimes/comments/1s0dfot/guardant_health_to_present_28_abstracts/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026", "text": "", "author": "Quantisnow", "score": 1, "num_comments": 0, "date": "2026-03-18", "url": "https://reddit.com/r/Quantisnow/comments/1rx23dm/guardant_health_to_present_28_abstracts/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership", "text": "", "author": "Quantisnow", "score": 1, "num_comments": 0, "date": "2026-03-16", "url": "https://reddit.com/r/Quantisnow/comments/1rv7mrt/guardant_health_launches_shield_multicancer/", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare", "text": "", "author": "Quantisnow", "score": 2, "num_comments": 0, "date": "2026-03-13", "url": "https://reddit.com/r/Quantisnow/comments/1rsljb0/new_guardant_healthharris_poll_survey_shows_92_of/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics", "text": "", "author": "Quantisnow", "score": 2, "num_comments": 0, "date": "2026-03-10", "url": "https://reddit.com/r/Quantisnow/comments/1rpv5qg/guardant_healths_shield_bloodbased_screening_test/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "reddit", "subreddit": "Penny_Stock_USA", "title": "Guardant’s new Shield screening tour shows blood-based testing is moving into real-world rollout", "text": "https://preview.redd.it/c09uxs4b52ng1.png?width=315&format=png&auto=webp&s=265801915d05560931fe4bd597ec820cbe50a057\n\nToday Guardant Health launched \"Shield Across America\", a coast-to-coast mobile screening tour that will bring its Shield colorectal cancer blood test to over 100 U.S. communities, with a stated focus on rural areas that have low screening rates and higher CRC incidence and mortality.\n\nGuardant is tying the rollout to real-world completion behavior, citing 93% patient adherence in", "author": "UnlicensedWizard78", "score": 2, "num_comments": 0, "date": "2026-03-04", "url": "https://reddit.com/r/Penny_Stock_USA/comments/1rkqiwn/guardants_new_shield_screening_tour_shows/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America", "text": "", "author": "Quantisnow", "score": 1, "num_comments": 0, "date": "2026-03-04", "url": "https://reddit.com/r/Quantisnow/comments/1rkjntr/guardant_health_launches_coasttocoast_screening/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened", "text": "", "author": "Quantisnow", "score": 1, "num_comments": 0, "date": "2026-03-03", "url": "https://reddit.com/r/Quantisnow/comments/1rjnjjd/actor_and_cancer_advocate_patrick_dempsey/", "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "reddit", "subreddit": "exactsciences", "title": "Exact Sciences Is Now Abbott!", "text": "As result of the Merger, on March 23, 2026, a change in control of Exact occurred, and Exact is now a direct, wholly owned subsidiary of Abbott Laboratories \n\nIt has been one heckuva run for long-time Exact Sciences shareholders! \n\nA roller coaster ride for sure at times. But always, for me at least, more than just an investment, but about being a part of the Company's mission to eradicate cancer and alleviate human suffering.\n\nAnd so many memories! \n\nWho can forget the fiasco in 2015, when Colo", "author": "Superchief440", "score": 16, "num_comments": 15, "date": "2026-03-23", "url": "https://reddit.com/r/exactsciences/comments/1s1mbwy/exact_sciences_is_now_abbott/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "heraldry", "title": "After a year, I'm ready for critiques!", "text": "Hello all! I started work on my assumed coat of arms this time last year, as trying to find if my Scottish ancestors possessed a COA was futile.\n\nAfter much research, deep contemplation, and countless edits, I think I finally have it right, and wishing for public opinion. I am open for your critiques! Before applying to and paying the $395 fee to the American College of Heraldry, as well as registering with the New England Committee on Heraldry, may I have your professional opinion and revi", "author": "EccentricArchivist", "score": 0, "num_comments": 17, "date": "2026-03-15", "url": "https://reddit.com/r/heraldry/comments/1ru63q2/after_a_year_im_ready_for_critiques/", "sentiment": { "label": "positive", "score": 0.42, "confidence": 0.42 } }, { "source": "reddit", "subreddit": "heraldry", "title": "Remade personal arms after last post", "text": "I wanted to make a coat of arms for my house, where I have rescued a lot of cats and dogs, which led to my online handle ''The Cat Fortress'' \n\nI wanted to incorporate green as it is my favorite color and the overall color palette accidentally (but fortuitously) reflects the colors of my country, Brazil\n\nFor the crest I went with a white cat with blue eyes to represent one of the nicest, best cats I've rescued, A white flamepoint named Brie which is an elderly cat\n\nwould you help me blazon this ", "author": "thecatfortress", "score": 56, "num_comments": 8, "date": "2026-03-24", "url": "https://reddit.com/r/heraldry/comments/1s2g5oz/remade_personal_arms_after_last_post/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "heraldry", "title": "Help blazoning mirrored sets of daggers in saltire", "text": "please forgive the quick sketch, i put it together just as an example... i have been wondering how to blazon two sets of daggers in saltire, one set being inverted, without being repetitive. \n\nthe rough draft i had come up with for this example is “**Argent a pale Sable, charged with a lion’s head erased guardant proper, between in chief two daggers in saltire inverted Argent and in base two daggers in saltire Argent**”. i am now trying to properly condense it.\n\nmy primary question: **is there a", "author": "cailleachsith", "score": 23, "num_comments": 8, "date": "2026-03-30", "url": "https://reddit.com/r/heraldry/comments/1s7riey/help_blazoning_mirrored_sets_of_daggers_in_saltire/", "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "reddit", "subreddit": "heraldry", "title": "How to blazon properly/order of words", "text": "This is a prototype of my arms, I have some tweaks to make of shades of colors, but they'll stay the same. \n\n \nI understand the components of it, but am confused on the order. I know its a field of argent, a beaver rampant proper, (how do you say holding) a key or, and then idk how to say on a azure Chevron, with a crest of a cat sejant argent)", "author": "Cadet-Cryyx", "score": 9, "num_comments": 7, "date": "2026-03-25", "url": "https://reddit.com/r/heraldry/comments/1s3cig9/how_to_blazon_properlyorder_of_words/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "heraldry", "title": "Book Suggestions on Heraldry..", "text": "Hi everybody, im collecting books on heraldry as much as find anywhere but most of them old editions with b&w editions which doesnt bring any good to comprehend the essence at all.\n\nRecently came across with [this one](https://www.amazon.com/Illustrated-Book-Heraldry-International-Contemporary/dp/0754834603/) (see the second pic and continuous ones) *Lorenz Books Publishing by Stephen Slater*. And seems pretty comprehensive. What do you think about it? Do you have any other suggestions?\n\nThank y", "author": "lastmonday07", "score": 32, "num_comments": 5, "date": "2026-03-18", "url": "https://reddit.com/r/heraldry/comments/1rxe188/book_suggestions_on_heraldry/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "heraldry", "title": "Coat of arms of a fictitious country, created in the style of Vexald [blazon, feedback]", "text": "Coat of arms of a fictitious country, created in the style of Vexald. \n\nDoes anyone have any feedback on or issues with its heraldic form (\"correctness\")? \n\nWould also be grateful if someone more knowledgeable than I am in this field would be so kind as to generate a blazon for the full achievement. The blade being held by the lion passant guardant in the crest and escutcheon is known as a keris, which is also present in the chief.", "author": "lanara-royal", "score": 30, "num_comments": 3, "date": "2026-03-28", "url": "https://reddit.com/r/heraldry/comments/1s5ussb/coat_of_arms_of_a_fictitious_country_created_in/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "reddit", "subreddit": "lungcancer", "title": "Bio marker testing", "text": "Hi \n\nMy mom 56F Asian with multiple pulmonary nodules was diagnosed with non small cell lung cancer. She is a non smoker. There is a high chance this is due to a mutation as per the pulmonologist. The oncologist that we are about to meet has sent the tissue and liquid biopsy to Caris. I have only heard of foundation one and guardant for lung cancer. Is Caris a good place to get biomarker testing done for lung cancer? Any insights or experiences with this company? ", "author": "Kind-Shake-953", "score": 10, "num_comments": 7, "date": "2026-03-14", "url": "https://reddit.com/r/lungcancer/comments/1rty5xk/bio_marker_testing/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "breastcancer", "title": "Reoccurrence?", "text": "Hi there awesome community!\n\nI’m 40 now with TCHP chemo, DMX, radiation and the exchange surgery completed in 2024. My doc has been doing regular Guardant tests and in August was the last negative result. The December one showed ctDNA at under 0.05% and bloodwork now shows my CA27.29 marker at 20 vs 10 in december (still in the green and only over 38 is it considered reason for stress).\n\nMy oncologist said they won’t take any action such as tests until the cancer marker is higher in bloodowrk or", "author": "AnnaMariaaaaaaa", "score": 5, "num_comments": 4, "date": "2026-03-12", "url": "https://reddit.com/r/breastcancer/comments/1rs6bfd/reoccurrence/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } } ] } }
\n
Frontend Focus
\n\n #​734 — March 25, 2026 | Read on the web\r\n\n